Send to

Choose Destination
Ann N Y Acad Sci. 2002 Apr;958:218-23.

Increased autoantibodies to SOX13 in Swedish patients with type 1 diabetes.

Author information

Department of Medicine, University of Lund, Lund, Sweden.


This article aims to estimate the prevalence of SOX13 antibodies in Swedish patients with type 1 diabetes and healthy controls. The patients (n = 102; median age 35 years [range, 9-89]) were newly diagnosed with type 1 diabetes in a defined area in southern Sweden during 1995-1998. Islet cell antibodies (ICA) were analyzed with immunofluorescence, while glutamic acid decarboxylase antibodies (GADA), tyrosine phosphatase antibodies (IA-2A), and antibodies against the transcription factor SOX13 (SOX13Ab) were analyzed with radioimmunoprecipitating assays. SOX13Ab were found in 9.8% (10/102) of type 1 patients compared to 2.0% (2/99) in healthy controls (P = 0.033). At least one of the four autoantibodies (ICA, GADA, IA-2A or SOX13Ab) were identified in 67% (68/102) of the patients. Samples positive for IA-2A were only in one case positive also for SOX13Ab. IA-2A-positive patients were often positive also for ICA and GADA (19/27), and the same combination was also common for SOX13Ab-positive patients (6/10). Only 2.0% (2/102) were positive for SOX13Ab alone. ICA, GADA and IA-2A were more frequent in younger patients (<or= 35 years of age) than in older patients, while SOX13Ab showed similar frequency in both groups. We concluded that the frequency of SOX13Ab was significantly increased in Swedish patients with type 1 diabetes, but that the addition of SOX13Ab to the combination of GADA and IA2-A only increased the sensitivity by 2% for autoimmune diabetes. Therefore, SOX13 could be a minor autoantigen involved in the pathogenesis of type 1 diabetes.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center